|
1
|
Didkowska J, Wojciechowska U, Manczuk M
and Łobaszewski J: Lung cancer epidemiology: Contemporary and
future challenges worldwide. Ann Transl Med. 4(150)2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 29 (Suppl 4):iv192–iv237. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Paz-Ares L, de Marinis F, Dediu M, Thomas
M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et
al: Maintenance therapy with pemetrexed plus best supportive care
versus placebo plus best supportive care after induction therapy
with pemetrexed plus cisplatin for advanced non-squamous
non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3,
randomised controlled trial. Lancet Oncol. 13:247–255.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gandhi L, Rodriguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Attili I, Passaro A, Pavan A, Conte P, De
Marinis F and Bonanno L: Combination immunotherapy strategies in
advanced non-small cell lung cancer (NSCLC): Does biological
rationale meet clinical needs? Crit Rev Oncol Hematol. 119:30–39.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Langer CJ: Emerging immunotherapies in the
treatment of non-small cell lung cancer (NSCLC): The role of immune
checkpoint inhibitors. Am J Clin Oncol. 38:422–430. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rocco D, Della Gravara L, Battiloro C and
Gridelli C: The role of combination chemo-immunotherapy in advanced
non-small cell lung cancer. Expert Rev Anticancer Ther. 19:561–568.
2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al: Pembrolizumab plus chemotherapy for squamous non-small-cell
lung cancer. N Engl J Med. 379:2040–2051. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yu W, Hua Y, Qiu H, Hao J, Zou K, Li Z, Hu
S, Guo P, Chen M, Sui S, et al: PD-L1 promotes tumor growth and
progression by activating WIP and β-catenin signaling pathways and
predicts poor prognosis in lung cancer. Cell Death Dis.
11(506)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mouw KW, Goldberg MS, Konstantinopoulos PA
and D'Andrea AD: DNA damage and repair biomarkers of immunotherapy
response. Cancer Discov. 7:675–693. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ricciuti B, Recondo G, Spurr LF, Li YY,
Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl
LM, et al: Impact of DNA damage response and repair (DDR) gene
mutations on efficacy of PD-(L)1 immune checkpoint inhibition in
non-small cell lung cancer. Clin Cancer Res. 26:4135–4142.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lamberti G, Andrini E, Sisi M, Federico AD
and Ricciuti B: Targeting DNA damage response and repair genes to
enhance anticancer immunotherapy: Rationale and clinical
implication. Future Oncol. 16:1751–1766. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gavande NS, VanderVere-Carozza PS, Hinshaw
HD, Jalal SI, Sears CR, Pawelczak KS and Turchi JJ: DNA repair
targeted therapy: The past or future of cancer treatment? Pharmacol
Ther. 160:65–83. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Blackford AN and Jackson SP: ATM, ATR, and
DNA-PK: The trinity at the heart of the DNA damage response. Mol
Cell. 66:801–817. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jette N and Lees-Miller SP: The
DNA-dependent protein kinase: A multifunctional protein kinase with
roles in DNA double strand break repair and mitosis. Prog Biophys
Mol Biol. 117:194–205. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Medová M, Medo M, Hovhannisyan L,
Muñoz-Maldonado C, Aebersold DM and Zimmer Y: DNA-PK in human
malignant disorders: Mechanisms and implications for
pharmacological interventions. Pharmacol Ther.
215(107617)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sak A, Stuschke M, Wurm R, Schroeder G,
Sinn B, Wolf G and Budach V: Selective inactivation of
DNA-dependent protein kinase with antisense oligodeoxynucleotides:
Consequences for the rejoining of radiation-induced DNA
double-strand breaks and radiosensitivity of human cancer cell
lines. Cancer Res. 62:6621–6624. 2002.PubMed/NCBI
|
|
24
|
Yanai M, Makino H, Ping B, Takeda K,
Tanaka N, Sakamoto T, Yamaguchi K, Kodani M, Yamasaki A, Igishi T
and Shimizu E: DNA-PK inhibition by NU7441 enhances
chemosensitivity to topoisomerase inhibitor in non-small cell lung
carcinoma cells by blocking DNA damage repair. Yonago Acta Med.
60:9–15. 2017.PubMed/NCBI
|
|
25
|
Azad A, Jackson S, Cullinane C, Natoli A,
Neilsen PM, Callen DF, Maira SM, Hackl W, McArthur GA and Solomon
B: Inhibition of DNA-dependent protein kinase induces accelerated
senescence in irradiated human cancer cells. Mol Cancer Res.
9:1696–1707. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hirsch FR, McElhinny A, Stanforth D,
Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P,
Hanks D, Vennapusa B, et al: PD-L1 immunohistochemistry assays for
lung cancer: Results from phase 1 of the blueprint PD-L1 IHC assay
comparison project. J Thorac Oncol. 12:208–222. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
The Cancer Genome Atlas Program-National
Cancer Institute. https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga.
Accessed February 20, 2021.
|
|
28
|
Tsao MS, Kerr KM, Kockx M, Beasley MB,
Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, et
al: PD-L1 immunohistochemistry comparability study in real-life
clinical samples: Results of blueprint phase 2 project. J Thor
Oncol. 13:1302–1311. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kintsler S, Cassataro MA, Drosch M,
Holenya P, Knuechel R and Braunschweig T: Expression of programmed
death ligand (PD-L1) in different tumors. Comparison of several
current available antibody clones and antibody profiling. Ann Diagn
Pathol. 41:24–37. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
D'Incecco A, Andreozzi M, Ludovini V,
Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J,
Coppi E, et al: PD-1 and PD-L1 expression in molecularly selected
non-small-cell lung cancer patients. Br J Cancer. 112:95–102.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Conforti F, Pala L, Bagnardi V, De Pas T,
Martinetti M, Viale G, Gelber RD and Goldhirsch A: Cancer
immunotherapy efficacy and patients' sex: A systematic review and
meta-analysis. Lancet Oncol. 19:737–746. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang S, Cowley LA and Liu XS: Sex
differences in cancer immunotherapy efficacy, biomarkers, and
therapeutic strategy. Molecules. 24(3214)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Oort J and Scheper RJ: Histopathology of
acute and chronic inflammation. Agents Actions. Suppl:25–30.
1977.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang
Z and Wang X: The diverse function of PD-1/PD-L pathway beyond
cancer. Front Immunol. 10(2298)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jubel JM, Barbati ZR, Burger C, Wirtz DC
and Schildberg FA: The role of PD-1 in acute and chronic infection.
Front Immunol. 11(487)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhang M, Li G and Wang Y and Wang Y, Zhao
S, Haihong P, Zhao H and Wang Y: PD-L1 expression in lung cancer
and its correlation with driver mutations: A meta-analysis. Sci
Rep. 7(10255)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Calles A, Liao X, Sholl LM, Rodig SJ,
Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, et
al: Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers
and never smokers with KRAS-mutant lung cancer. J Thor Oncol.
10:1726–1735. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Pawelczyk K, Piotrowska A, Ciesielska U,
Jablonska K, Gletzel-Plucinska N, Grzegrzolka J, Podhorska-Okolow
M, Dziegiel P and Nowinska K: Role of PD-L1 expression in non-small
cell lung cancer and their prognostic significance according to
clinicopathological factors and diagnostic markers. Int J Mol Sci.
20(824)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
McLaughlin J, Han G, Schalper KA,
Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R,
LoRusso P and Rimm DL: Quantitative assessment of the heterogeneity
of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol.
2:46–54. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Mohiuddin IS and Kang MH: DNA-PK as an
emerging therapeutic target in cancer. Front Oncol.
9(635)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Goodwin JF and Knudsen KE: Beyond DNA
repair: DNA-PK function in cancer. Cancer Discov. 4:1126–1139.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Li L, Zhu T, Gao YF, Zheng W, Wang CJ,
Xiao L, Huang MS, Yin JY, Zhou HH and Liu ZQ: Targeting DNA damage
response in the radio(Chemo)therapy of non-small cell lung cancer.
Int J Mol Sci. 17(839)2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kase M, Vardja M, Lipping A, Asser T and
Jaal J: Impact of PARP-1 and DNA-PK expression on survival in
patients with glioblastoma multiforme. Radiother Oncol.
101:127–131. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Xing J, Wu X, Vaporciyan AA, Spitz MR and
Gu J: Prognostic significance of ataxia-telangiectasia mutated,
DNA-dependent protein kinase catalytic subunit, and Ku
heterodimeric regulatory complex 86-kD subunit expression in
patients with nonsmall cell lung cancer. Cancer. 112:2756–2764.
2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hu S, Qu Y, Xu X, Xu Q, Geng J and Xu J:
Nuclear survivin and its relationship to DNA damage repair genes in
non-small cell lung cancer investigated using tissue array. PLoS
One. 8(e74161)2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Osoegawa A, Hiraishi H, Hashimoto T,
Takumi Y, Abe M, Takeuchi H, Miyawaki M, Okamoto T and Sugio K: The
positive relationship between γH2AX and PD-L1 expression in lung
squamous cell carcinoma. In Vivo. 32:171–177. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Sato H, Niimi A, Yasuhara T, Permata TBM,
Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, et al:
DNA double-strand break repair pathway regulates PD-L1 expression
in cancer cells. Nat Commun. 8(1751)2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Damia G: Targeting DNA-PK in cancer. Mutat
Res. 821(111692)2020.PubMed/NCBI View Article : Google Scholar
|
